NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the publication of a case report in Oncogene from its phase 1/2 study in patients with advanced solid tumors where one infusion of agenT-797 in gastric cancer refractory to anti-PD1 led to a durable confirmed partial response, highlighting the unique potential of iNKT cells to overcome resistance to immune checkpoint inhibitors (ICIs).

2024年1月30日，纽约（环球通讯社）--MiNK Therapeutics，Inc.（纳斯达克：INKT），一家临床阶段的生物制药公司，率先发现，开发和商业化同种异体，现成的不变自然杀伤T（INKT）细胞疗法，以治疗癌症和其他免疫介导的疾病，今天宣布，在晚期实体瘤患者的1/2期研究中，Oncogene发表了一份病例报告，其中在抗PD1难治的胃癌中输注一剂797导致持久的部分反应，突出了iNKT细胞克服免疫检查点抑制剂（ICI）耐药性的独特潜力。

“Gastric cancer remains an area of high unmet need, where the majority of patients develop disease progression related to tumor resistance,” said Dr. Benedito A. Carneiro, Director of Clinical Research, Director of Cancer Drug Development (Phase I), Associate Director of the Division of Hematology/Oncology, Legorreta Cancer Center at Brown University.

布朗大学Legorreta癌症中心临床研究主任、癌症药物开发主任（第一阶段）副主任Benedito A.Carneiro博士说：“胃癌仍然是一个未满足需求的领域，大多数患者会发展出与肿瘤耐药性相关的疾病进展。”。

“Novel therapeutic approaches, like allogeneic iNKT cells, are urgently needed to overcome resistance to immune checkpoint inhibitors in gastric cancers and other refractory solid tumors. The activity, tolerability, and ease of off-the-shelf administration of iNKT-based cell therapies position them as an attractive approach for overcoming cancer resistance.” Gastric cancer, the fifth most common malignancy globally, is incurable with only 12% responsive to ICIs1,2.

“迫切需要新的治疗方法，如同种异体iNKT细胞，以克服胃癌和其他难治性实体瘤对免疫检查点抑制剂的耐药性。基于iNKT的细胞疗法的活性，耐受性和易于现成给药，使其成为克服癌症耐药性的有吸引力的方法。”胃癌，全球第五大最常见的恶性肿瘤是无法治愈的，只有12%对ICIs1,2有反应。

This phase study (NCT05108623) was designed to evaluate agenT-797, an unmodified iNKT cell therapy, in solid tumors refractory to ICIs. Patients received a single dose of agenT-797, without lymphodepletion, either alone or in combination with pembrolizumab or nivolumab. This case report describes a d.

该阶段研究（NCT05108623）旨在评估未经修饰的iNKT细胞疗法agenT-797在ICI难治性实体瘤中的作用。患者单独或与pembrolizumab或nivolumab联合接受单剂量的药物-797，无淋巴清除。该病例报告描述了d。